# US 2006/0067888 A1 · Immunogenic glycopeptides, screening, preparation and uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0067888 A1
- Document ID: US20060067888A1
- Status: Published application
- Kind: A1
- Application number: 10/953,095
- Filed: 2004-09-30
- Published: 2006-03-30
- Earliest claimed: 2004-09-30
- Assignees: Institut Pasteur
- Inventors: Gilles Marchal; Felix Romain; Pascale Pescher; Francoise Baleux; Daniel Scott-Algara; Laurence Mulard
- Web page: https://patentgrep.com/patent/US20060067888A1

## CPC

- G01N 33/5695: {Mycobacteria}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to immunogenic glycopeptides derived from pathogenic microorganisms, which can be used for immunization and diagnosing infections dye to such pathogenic microorganisms and also to method for the selection and preparation thereof.

## Claims

### Claim 1

A method for diagnosing an infection in a patient likely to be infected with a pathogenic microorganism, comprising the detection of CD4+ T lymphocytes recognizing at least one glycopeptide, selected from the group consisting of:
a1) a glycopeptide essentially consisting of a glycosylated T epitope, comprising from 14 to 25 amino acids, among which at least one neutral amino acid is bonded to a disaccharide or to a trisaccharide, and at least 15% of said amino acids are prolines, one of the prolines being located in position -1 to -4, relative to the position of said neutral amino acid, which glycopeptides, derived from a pathogenic microorganism; and
b1) a glycopeptide having a sequence of 15 to 39 amino acids which includes the sequence of the glycopeptide as defined in a1).

### Claim 2 (depends on 1)

The method according to claim 1, comprising:
administering said glycopeptide(s) to the patient, and
detecting CD4+ T lymphocytes recognizing said glycopeptide(s).

### Claim 3 (depends on 1)

The method according to claim 1, comprising:
bringing a biological sample from said patient into contact with said glycopeptide(s), and
detecting CD4+ T lymphocytes recognizing said glycopeptide(s).

### Claim 4 (depends on 1)

The method according to claim 1, wherein said detection is carried out by a lymphocyte proliferation assay.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said detection is carried out by a cytokine assay.

### Claim 6 (depends on 2)

The method according to claim 2, wherein said detection is carried out by a delayed-type hypersensitivity assay.

### Claim 7 (depends on 3)

The method according to claim 3, wherein said biological sample consists of peripheral blood mononuclear cells.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said neutral amino is selected from the group consisting of serine and threonine.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said glycopeptide contains from 1 to 7 threonine residues bonded to a disaccharide or to a trisaccharide.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said disaccharide or trisaccharide is a dimer or a trimer of hexose.

### Claim 11 (depends on 10)

The method according to claim 10,
wherein said hexose is a mannose.

### Claim 12 (depends on 1)

The method according to claim 1, wherein said neutral amino is bonded by an α-(1,2) glycosidic bond.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said glycopeptide is derived from a pathogenic microorganism capable of O-glycosylating proteins.

### Claim 14 (depends on 1)

The method according to claim 1, wherein said glycopeptide is derived from Candida albicans.

### Claim 15 (depends on 1)

The method according to claim 1, wherein said glycopeptide is derived Mycobacterium tuberculosis.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said glycopeptide is derived from the Apa protein of M. tuberculosis (Genbank number X80268) or from the Rv1796 protein encoded by the Rv 1796 gene, with reference to the annotation of the sequence of the genome of M. tuberculosis strain H37Rv.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said glycopeptide is selected from the group consisting of:
a 39 amino acid glycopeptide, the sequence (SEQ ID NO:1) of which is that which extends from positions 1 to 39 of the sequence of the Apa protein and in which at least one of the threonine residues in position 10, 18 and 27 of SEQ ID NO:1 is bonded to a disaccharide or trisaccharide via a glycosidic bond, a 26 amino acid glycopeptide, the sequence (SEQ ID NO:2) of which is that which extends from positions 261 to 286 of the sequence of the Apa protein (C-terminal sequence) and in which the threonine residue in position 17 of SEQ ID NO:2 is bonded to a disaccharide or trisaccharide via a glycosidic bond, and
a 35 amino acid glycopeptide, the sequence (SEQ ID NO:3) of which is that which extends from positions 169 to 203 of the sequence of the Rv 1796 protein and in which at least one of the threonine residues in position 4, 5, 7, 13, 15, 23 and 25 of SEQ ID NO:3 is bonded to a disaccharide or trisaccharide via a glycosidic bond.

### Claim 18 (depends on 15)

The method according to claim 15, which is a method for diagnosing tuberculosis, comprising:
administering said glycopeptide(s) derived from Mycobacterium tuberculosis to the patient, and
detecting CD4+ T lymphocytes recognizing said glycopeptide(s) by a delayed-type hypersensitivity assay.

### Claim 19 (depends on 15)

The method according to claim 15, which is a method for diagnosing tuberculosis, comprising:
bringing a biological sample from said patient into contact with said glycopeptide(s) derived from Mycobacterium tuberculosis, and
detecting CD4+ T lymphocytes recognizing said glycopeptide(s).

### Claim 20

A kit for diagnosing an infection in a patient likely to be infected with a pathogenic microorganism, comprising at least a glycopeptideselected from the group consisting of:
a1) a glycopeptide essentially consisting of a glycosylated T epitope, comprising from 14 to 25 amino acids, among which at least one neutral amino acid is bonded to a disaccharide or to a trisaccharide, and at least 15% of said amino acids are prolines, one of the prolines being located in position -1 to -4, relative to the position of said neutral amino acid, which glycopeptides, derived from a pathogenic microorganism; and
b1) a glycopeptide having a sequence of 15 to 39 amino acids which includes the sequence of the glycopeptide as defined in a1).

### Claim 21 (depends on 20)

A kit according to claim 20, which is a kit for diagnosing tuberculosis, comprising a glycopeptide derived from M. tuberculosis.
